Retia Medical LLC of Valhalla, NY at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

Retia Medical LLC

7 Dana Road, Suite 111, 10595 Valhalla, NY
Telephone +1 914 5941986

This company is co-exhibitor of
Messe Düsseldorf North America

Hall map

MEDICA 2018 hall map (Hall 16): stand E32-13

Fairground map

MEDICA 2018 fairground map: Hall 16

Our range of products

Product categories

  • 01  Electromedical Equipment / Medical Technology
  • 01.06  Intense medicine / anesthesiology / respiration
  • 01.06.03  Patient monitoring systems

Patient monitoring systems

Our products

Product category: Patient monitoring systems


Retia has created a new, less-invasive system to monitor cardiac outpt (CO) and other key hemodynamic parameters accurately when patients go unstable. By monitoring changes in CO, clinicians can detect, diagnose and treat life-threatening conditions better, leading to improved outcomes and lower costs. The patented platform technology behind Retia's monitor was licensed exclusively from Michigan State and MIT.

The Retia Monitor connects to existing radial arterial catheters, which are routinely placed in high-risk patients in the OR and ICU (95% of the time in the US). 

The Retia Monitor offers early detection of changes in CO by processing existing peripheral blood pressure signals using a proprietary algorithm. This approach is called "pulse contour analysis." Retia's algorithm models blood circulation and accounts for beat-to-beat variations in the blood pressure signal. These variations, ignored in other pulse contour algorithms, turn out to be critical to the calculation of CO. Retia also uses additional non-invasive sensors to help the monitor to maintain its accuracy during severe vasodilation or vasoconstriction. Other competing system are actually contraindicated during these situations and have been shown to fail dramatically in numerous, clinically-relevant situations. The Retia algorithm has been validated in animals across a wide range of hemodynamic conditions and in over 300 human subjects, including the critically ill.

Selected results:
•12.9% calibrated CO error compared to aortic flow probe in 6 animals during drug and volume interventions
     [IEEE Trans Biomed Eng, 53(3):459, 2006]    
•15.1% calibrated CO error compared to Doppler ultrasound in 10 healthy humans during drug and postural interventions
     [J Appl Physiol, 101:598, 2006]
•Reliable tracking of CO reductions in 129 healthy humans during central hypovolemia
     [Br J Anaesth, 106(1):23, 2011]
•18.5% calibrated CO error compared to pulmonary artery catheter (single bolus thermodilution) in 184 critically ill patients
     [Br J Anaesth, doi: 10.1093/bja/aes099, 2012]

By comparison current products have large failures in key clinical situations including:
1. Hemorrhage
2. Sepsis
3. End stage liver failure and liver transplants - these have large fluid shifts and other hemodynamic changes
4. Hypothermia
5. Post-op high-risk surgery

More Less

About us

Company details

Our mission is to improve patient outcomes by enabling accurate detection of changes in cardiovascular status.

More Less